Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 119 clinical trials
None
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (Arm A) compared with that of combination of pomalidomide, bortezomib

cancer
measurable disease
bortezomib
refractory multiple myeloma
lenalidomide
  • 2 views
  • 26 Jul, 2021
  • 74 locations
None
A Study of Combination Therapy With Venetoclax Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

This is a study of venetoclax, daratumumab, and dexamethasone with and without bortezomib combination therapy to evaluate safety, tolerability, and efficacy of these combinations in participants

bone marrow procedure
measurable disease
bortezomib
refractory multiple myeloma
daratumumab
  • 97 views
  • 29 Nov, 2021
  • 70 locations
None
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma the EQUATE Trial

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and

measurable disease
cancer
bortezomib
bone marrow procedure
chemotherapy drugs
  • 0 views
  • 05 Dec, 2021
  • 377 locations
None
  • 0 views
  • 05 Dec, 2021
  • 16 locations
None
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

treatment and remission gets shorter after each line of treatment. This is a study to determine recommended Phase 2 dose and change in disease symptoms of eftozanermin alfa in combination with bortezomib

cancer
measurable disease
bortezomib
refractory multiple myeloma
dexamethasone
  • 0 views
  • 10 Oct, 2021
  • 34 locations
None
A Study of Bortezomib Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel

human chorionic gonadotropin
measurable disease
lenalidomide
chemotherapy regimen
fludarabine
  • 3 views
  • 05 Dec, 2021
  • 133 locations
None
To Evaluate Safety Tolerability and Clinical Activity of the Antibody-drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A) or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

(Arm A)] or Bortezomib Plus Dexamethasone [Bor/Dex (Arm B)] in participants with RRMM, i.e., those who have relapsed or who are refractory to at least 1 line of approved therapy. Part 1 of the study

progressive disease
measurable disease
refractory multiple myeloma
lenalidomide
revlimid
  • 42 views
  • 29 May, 2021
  • 28 locations
None
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

This study will evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide

measurable disease
lenalidomide
chemotherapy regimen
high dose chemotherapy
neutrophil count
  • 14 views
  • 30 Jul, 2021
  • 38 locations
None
Selinexor and Backbone Treatments of Multiple Myeloma Patients

>Arm 2: Selinexor + dexamethasone + bortezomib (SVd); enrollment complete Arm 3: Selinexor + dexamethasone + lenalidomide (SRd) in RRMM; enrollment complete Arm 4: Selinexor

measurable disease
immunomodulatory imide drug
refractory multiple myeloma
pomalidomide
elotuzumab
  • 57 views
  • 05 Dec, 2021
  • 24 locations
None
Daratumumab Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma

Myeloma patients who relapse after prior treatment with bortezomib and lenalidomide have survival of less than 1 year. A number of new drugs have been approved for the treatment of relapse

  • 81 views
  • 22 Jan, 2021
  • 3 locations